Reviewer’s report

Title: Triptorelin Relieves Lower Urinary Tract Symptoms in Chinese Advanced Prostate Cancer Patients: a Multicenter, Non-interventional, Prospective Study

Version: 0 Date: 22 Aug 2017

Reviewer: Vincent De Ruyter

Reviewer’s report:

132 : please add ... has not yet been studied in this specific population

138 : It should be stated in the methodology that patients could have had surgery in the past (is mentioned in line 248-251 but not clear in methods)

138 : It is not clear if a combination therapy of radiotherapy and triptorelin was allowed during the study as this might also influence LUTS

230 : The author states that 25.4 % of the patients received concomitant medication. It is not clear whether this is bicalutamide or other medication that might influence LUTS such as 5-alpha reductase inhibitors or alpha-1 blockers

234-235 : I have questions regarding the conduct of this study since of the 398 patients that were included, 120 had major protocol violations

303 : No adverse events seems not possible, that means that of the 398 patients included, not 1 single person had flushes ?

324 : Perhaps not in the Chinese population but there have recently been several publications on this topic

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have received salary from Ipsen, the sponsor of this manuscript

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal